News
The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...
July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...
The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by r ...
New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...
The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...
Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...
Both Wegovy and Ozempic are semaglutide – a drug that first entered the US market in 2017 as a diabetes medication. It was quickly hyped online as the secret to celebrities achieving extreme thinness.
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
The Delhi High Court on Tuesday disposed of a public interest litigation (PIL) raising alarm over the off-label and ...
Senior Advocate Diya Kapur, representing the petitioner, informed the court that some gyms were promoting these drugs as a ...
Joe Gebbia, a confidant of the technology billionaire and a Tesla director, is also a leader of the federal cost-cutting team ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results